Diagnostics group Novacyt develops new tests to detect Covid-19, bird flu, Health News, ET HealthWorld

PARIS: Clinical diagnostics group Novacyt , one of many healthcare companies whose shares have surged during the coronavirus pandemic, announced on Monday that it was developing three new tests to detect Covid-19 and bird flu.

The company said it was launching a research-use-only (RUO) polymerase chain reaction (PCR) test for a new strain of Covid-19, and developing two other new RUO PCR tests for avian influenza following recent outbreaks across Europe.

Novacyt’s Paris-listed shares have surged by around 5,490% since the start of 2020, giving the company a market capitalisation of around 668 million euros ($810.8 million).

Follow and connect with us on , Facebook, Linkedin





Source link